Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: N Engl J Med. 2015 May 31;373(1):23–34. doi: 10.1056/NEJMoa1504030

Figure 1. Progression-free Survival.

Figure 1

Figure 1

Figure 1

Panel A shows the Kaplan–Meier curves for progression-free survival in the intention-to-treat population. Patients were followed for a minimum of 9 months. Panels B and C show the Kaplan–Meier curves for progression-free survival in patients with PD-L1-positive and PD-L1-negative tumors, respectively.

[Please note: the KM curves shown in the graph below are based on verified PD-L1 assay data. The graphs will be updated based on validated PD-L1 data, although it is expected that there will be little difference between the verified and validated graphs.]

[Please note: the KM curves shown in the graph below are based on verified PD-L1 assay data. The graphs will be updated based on validated PD-L1 data, although it is expected that there will be little difference between the verified and validated graphs.]